Abstract
Background: Major Depressive disorder (MDD) is often accompanied by cognitive deficits, involving attention, learning, memory and executive functioning. Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) show efficacy on affective symptoms, but it is unclear whether or not they improve cognitive symptoms.
Methods: We carried out a 12 week-prospective observational study in two cohorts of recurrent moderate-severe partial responder MDD patients, to test the hypothesis that SSRIs and/or SNRIs may affect cognitive symptoms and assess whether or not such an effect was correlated to their effect on affective symptoms. All patients underwent cognitive and neuropsychiatric assessment at baseline, 4- and 12-week follow-up. Thirty-three patients in the SSRI- and sixteen patients in the SNRI-cohort completed the follow-up.
Results: Both SSRIs and SNRIs reduced affective symptoms and improved global cognitive function. Both SSRIs and SNRIs improved executive function and verbal memory. Global cognitive function, verbal memory and executive function improved both in full and partial responder patients. Finally, there was no correlation between baseline Mini Mental State Examination, Montreal Cognitive Assessment and Frontal Assessment Battery scores and the mean change in Hamilton Psychiatric Rating scale for Depression or Beck Depression Inventory at the end of the 12 weeks of treatment.
Conclusion: Present data show that SSRIs and SNRIs improve cognitive symptoms in MDD independently from their efficacy on affective symptoms. Affective and cognitive symptoms may represent distinct psychopathological dimensions of MDD with different response to antidepressant drugs.
Keywords: Affective symptoms, antidepressant drugs, cognition, major depression, psychometric tools, Selective Serotonin Reuptake Inhibitors, Serotonin and Noradrenaline Reuptake Inhibitors.
CNS & Neurological Disorders - Drug Targets
Title:Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study
Volume: 15 Issue: 10
Author(s): Sabrina Castellano, Andrea Ventimiglia, Salvatore Salomone, Andrea Ventimiglia, Simona De Vivo, Maria Salvina Signorelli, Elisa Bellelli, Mario Santagati, Rita Anna Cantarella, Enrica Fazio, Eugenio Aguglia, Filippo Drago, Santo Di Nuovo and Filippo Caraci
Affiliation:
Keywords: Affective symptoms, antidepressant drugs, cognition, major depression, psychometric tools, Selective Serotonin Reuptake Inhibitors, Serotonin and Noradrenaline Reuptake Inhibitors.
Abstract: Background: Major Depressive disorder (MDD) is often accompanied by cognitive deficits, involving attention, learning, memory and executive functioning. Selective Serotonin Reuptake Inhibitors (SSRIs) and Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) show efficacy on affective symptoms, but it is unclear whether or not they improve cognitive symptoms.
Methods: We carried out a 12 week-prospective observational study in two cohorts of recurrent moderate-severe partial responder MDD patients, to test the hypothesis that SSRIs and/or SNRIs may affect cognitive symptoms and assess whether or not such an effect was correlated to their effect on affective symptoms. All patients underwent cognitive and neuropsychiatric assessment at baseline, 4- and 12-week follow-up. Thirty-three patients in the SSRI- and sixteen patients in the SNRI-cohort completed the follow-up.
Results: Both SSRIs and SNRIs reduced affective symptoms and improved global cognitive function. Both SSRIs and SNRIs improved executive function and verbal memory. Global cognitive function, verbal memory and executive function improved both in full and partial responder patients. Finally, there was no correlation between baseline Mini Mental State Examination, Montreal Cognitive Assessment and Frontal Assessment Battery scores and the mean change in Hamilton Psychiatric Rating scale for Depression or Beck Depression Inventory at the end of the 12 weeks of treatment.
Conclusion: Present data show that SSRIs and SNRIs improve cognitive symptoms in MDD independently from their efficacy on affective symptoms. Affective and cognitive symptoms may represent distinct psychopathological dimensions of MDD with different response to antidepressant drugs.
Export Options
About this article
Cite this article as:
Castellano Sabrina, Ventimiglia Andrea, Salomone Salvatore, Ventimiglia Andrea, Vivo De Simona, Signorelli Salvina Maria, Bellelli Elisa, Santagati Mario, Cantarella Anna Rita, Fazio Enrica, Aguglia Eugenio, Drago Filippo, Nuovo Di Santo and Caraci Filippo, Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study, CNS & Neurological Disorders - Drug Targets 2016; 15 (10) . https://dx.doi.org/10.2174/1871527315666161003170312
DOI https://dx.doi.org/10.2174/1871527315666161003170312 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Measurement of Serum Monoamine Oxidase in Lichen Planus Patients and Its Clinical Significance
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Takotsubo Syndrome: Clinical Manifestations, Etiology and Pathogenesis
Current Cardiology Reviews Palmitoylethanolamide Reduces Formalin-Induced Neuropathic-Like Behaviour Through Spinal Glial/Microglial Phenotypical Changes in Mice
CNS & Neurological Disorders - Drug Targets TLR2 and TLR4 Expression During Bacterial Infections
Current Pharmaceutical Design Fibromyalgia: Mechanisms, Current Treatment and Animal Models
Current Pharmaceutical Biotechnology Structure-Activity Relationships of Biphalin Analogs and their Biological Evaluation on Opioid Receptors
Mini-Reviews in Medicinal Chemistry Fragile X Syndrome and Autism: Common Developmental Pathways?
Current Pediatric Reviews Transgenic Mice as a Model of Pre-Clinical Alzheimers Disease
Current Alzheimer Research Simultaneous Interruption of Signal Transduction and Cell Cycle Regulatory Pathways: Implications for New Approaches to the Treatment of Childhood Leukemias
Current Drug Targets Nociceptinergic System as Potential Target in Parkinson’s Disease
Mini-Reviews in Medicinal Chemistry Editorial: Improving Neuropharmacology using Big Data, Machine Learning and Computational Algorithms
Current Neuropharmacology Perspectives for Drug Intervention in Amyloid Diseases
Current Drug Targets TRP Channels in Respiratory Pathophysiology: the Role of Oxidative, Chemical Irritant and Temperature Stimuli
Current Neuropharmacology Meet Our Editorial Board Member
CNS & Neurological Disorders - Drug Targets Achieving Detumescence of Ischemic Priapism with Intra-Cavernosal Injection of entanyl: An Unexpected Outcome of Miscommunication Error
Current Drug Safety Vascular Endothelial Growth Factor and Angiopoietins in Neurovascular Regeneration and Protection Following Stroke
Current Neurovascular Research Can't Always Get What you Want? Try an Indirect Route you Just Might Get What you Need: A Study on Access to Genetic Data by Canadian Life Insurers
Current Pharmacogenomics and Personalized Medicine Autophagy to the Rescue
Current Neurovascular Research Role of Estradiol in the Expression of Genes Involved in Serotonin Neurotransmission: Implications for Female Depression
Current Neuropharmacology Daily Melatonin Administration Attenuates Age-Dependent Disturbances of Cardiovascular Rhythms
Current Aging Science